Cellsway logo

Cellsway

Liquid biopsy for cancer monitoring through isolation and counting Circulating Tumor Cells (CTCs) from blood.

5 employees · est. 2020 · Ankara, United Kingdom

VS
Exosome Diagnostics, a Bio-Techne brand logo

Exosome Diagnostics, a Bio-Techne brand

ExoDx Prostate is the only exosome-based, non-DRE, simple urine test to assess risk for HGPCa and guide biopsy decision.

103 employees · est. 2008 · Waltham, United States

Exosome Diagnostics, a Bio-Techne brand is the older company (2020 vs 2008); Exosome Diagnostics, a Bio-Techne brand is the larger of the two.

Side-by-Side Comparison

Cellsway Exosome Diagnostics, a Bio-Techne brand
Founded
2020 2008 older
Headquarters
Ankara, United Kingdom Waltham, United States
Employees
5 103 larger
Industry
Biotechnology, Health Care Biotechnology, Health Care
Funding Stage
Unknown Series C
Total Funding
$1.45M $112.08M
Funding Rounds
5 6
Services
CTC Liquid Biopsy Platform, CTC Enrichment Device, CTC Test Panels Not tracked yet
Target Customers
Oncologists, Cancer Research Laboratories, Healthcare Institutions, Service Laboratories Not tracked yet
Taxonomy
Liquid Biopsy, Circulating Tumor Cells, Cancer Monitoring, Cancer Diagnostics, Microfluidic Technology, Lab-on-a-Chip, Biomedical Engineering, Minimally Invasive Diagnostics, Cancer Research, CTC Isolation, CTC Enumeration, Cancer Management, Deep-Tech Startup Exosome-based Diagnostics, Liquid Biopsy, Prostate Cancer, Biopsy Decision, Molecular Diagnostics, Minimally Invasive, Nucleic Acid Profiles, Cancer Detection, Urine Test, Blood Test, Cancer Therapies, Non-invasive Testing, Cancer Biomarkers, Precision Medicine
Website
cellsway.com exosomedx.com
Cellsway logo

About Cellsway

Cellsway is a promising deep-tech startup, established in March 2020 in the UK, with a focus on revolutionizing cancer diagnostics and management. The company has successfully translated its expertise from Mikro Biyosistemler Inc. into a commercial product aimed at setting a new gold standard in the...

Exosome Diagnostics, a Bio-Techne brand logo

About Exosome Diagnostics, a Bio-Techne brand

Exosome Diagnostics, Inc., founded in 2008 and headquartered in the United States, is making significant strides in the biotechnology and healthcare industries. The company's slogan, "ExoDx Prostate is the only exosome-based, non-DRE, simple urine test to assess risk for HGPCa and guide biopsy decis...

We will tell you when either one moves

BounceWatch watches Cellsway and Exosome Diagnostics, a Bio-Techne brand for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at Cellsway and Exosome Diagnostics, a... — by email.

Frequently Asked Questions

Cellsway — Liquid biopsy for cancer monitoring through isolation and counting Circulating Tumor Cells (CTCs) from blood.. Exosome Diagnostics, a Bio-Techne brand — ExoDx Prostate is the only exosome-based, non-DRE, simple urine test to assess risk for HGPCa and guide biopsy decision.. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Cellsway has raised $1.45M while Exosome Diagnostics, a Bio-Techne brand has raised $112.08M.
Cellsway and Exosome Diagnostics, a Bio-Techne brand operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Cellsway with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at Cellsway on 6 Feb 2026, and Exosome Diagnostics, a Bio-Techne brand on 12 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy